New research indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end conventional diet and exercise programs.
Published data in a leading medical journal demonstrates that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People using such drugs should be informed of the potential of rapid rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to starting weight in about a year and a half.
Comparing Treatments
The research, which examined 37 of studies involving thousands of participants, compared the results of the injectable medications with older methods.
Scientists note that individuals who shed pounds through dieting generally experience a less rapid creep back—approximately 100 grams monthly—once they finish.
Explaining the Quick Rebound
Doctors believe the way of the drugs accounts for the amplified weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels several times higher than normal might result in the system to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in appetite is uncontrolled, making overeating much more probable."
An Ongoing Disease?
Health authorities recommend the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, due to the likelihood of relapse, the treatment should be considered ongoing.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the chronic nature of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Individuals who have stopped the jabs explain a powerful resurgence of hunger.
"It was like something activating and you become starving," recalled one woman.
The struggle is compounded if individuals have not established sustainable dietary or behavioural changes during therapy.
Significant Adoption
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, experts stress that while these medications are potent tools for weight loss, they are not a permanent cure and lasting health benefits relies on ongoing behavioural support.
